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Abstract 
The current study intends to present the relevance of omeprazole, esomeprazole, rabeprazole, pantoprazole and 
lansoprazole by means of the technological foresight study, through invention patent documents from Brazilian applicants 
as indicators of innovation. The European database of patents (Espacenet), Word Patent Index (DERWENT) and the 
Brazilian Patent Base of INPI were used, combining keywords and International Patent Classifications. The major 
applicants, countries of publication and claims categories were mapped. The 212 patent requests collected are mainly 
distributed in Chemistry, Pharmacy and Pharmacology areas. The results obtained revealed that the US was the main 
country with studies directed to this technological area (59 patent applications) and the major applicant was the company 
Astrazeneca AB. Therefore, we can understand that this is a promising technology that may reflect in an increase of R&D 
activities and patent applications in this area. 
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Introduction 
James M. Utterback and William J. Abernathy (2004) 
present historical studies of innovations in their 
organizational environments, technical and economic. 
Describe how changes occur according to patterns 
observed in various industries and sectors. It is considered 
that the model incorporates the realities of the market, 
enabling an evaluation of several conditions necessary for 
rapid innovation with high levels of production and 
productivity. 
According to Joseph Schumpeter, innovation is not the 
same as invention. Innovation can be considered the first 
commercial use of new product, process, device or 
system. Kline & Rosenberg (1986), reports that innovation 
is any change in the socio-technical manufacturing, 
distribution or use which allows an improvement in terms 
of cost, quality or service to consumers and employees, 
considering the degree of uncertainty to achieve success 
and the life cycle stage in which the products are found.  
Regarding product innovations, Utterback (1994) notes 
that the so-called "Hard innovation" in the product 
eventually ends with the consolidation of a dominant 
design as the market has its expectations for the product 
in terms of features, format, and specific skills, in other 
words, product innovations become much smaller, where 
the focus of Research and Development is on "incremental 
innovations" of the existing features that will be 
standardized. 
The basic premise for any country to develop technological 
advance activities is having a sharp scientific and 
technological qualification. In this context, Brazil has 
gradually supported the development of scientific activities 
that allow technological growth in various areas, making 
new products like pharmaceuticals to be developed, and 
being of fundamental importance to population.  
The pharmaceutical area is a research-intensive industry, 
which means they are always doing research, and 
throughout history they have presented a fast innovation 
rate implemented by companies in relation to other 
institutions. The release of new or enhanced products 
represents a key element in the pattern of industry 
competition, particularly in the pharmaceutical industry, 
allowing technological innovation, demanding heavy 
investments in research and development and that also 
relies on the International Intellectual Property System and 
massive marketing and advertising costs  (Carvalho, D. S. et 
al. 2009). 
Facing the world’s demands for new compounds and 
therapeutic methods that prevent and treat diseases 
whose treatments are still a challenge to scientists 
nowadays (like: cancer, AIDS, cardiovascular diseases, 
among others), together with the high cost of biopolymers 
to pharmaceutical use; it is necessary to develop new 
technologies using these biopolymers as pharmaceutics. 
And, as part of the technological innovation development 
process, the new technologies must be protected utilizing 
patent rights.    
Tidd et al. (1997) consider that the core competences of 
firms are not always sufficient for the development of new 
products. In technological trajectories companies should 
not remain stagnant in their core competencies or 
distinctive, overlooking or underestimating the new basic 
skills for the operation of future technological 
opportunities, they need to develop links with the outside 
world. 
The use of omeprazole is important in the pharmaceutical 
industry, it is important to assess how it is implemented 
and how the development of research and development 
(R&D) in the area was. In this context, the patent 
applications are among the most reliable and 
comprehensive sources of formal information when R&D, 
technology, and innovation are analyzed. Patents can be 
considered indicators of R&D in a particular industry and 
thus are directly related to the process of technological 
innovation, therefore, the information contained in these 
documents are essential for evaluating the technological 
overview in a particular area. 
For a better analysis of patent applications, techniques 
applied in technological forecasting studies, such as 
monitoring and bibliographic studies are the most suitable, 
especially by the systematic use and because they have pre-
established procedures worldwide, making research 
comparable with other studies in the area. 
Technological foresight is the term applied in studies that 
try to anticipate and understand the potentialities, 
evolutions, characteristics, and effects of technological 
changes, particularly its invention, adoption and usage. 
Thus, through it, it is possible to try to anticipate the 
technological and scientific advances and participate in a 
way to influence in the guidance of technological 
trajectories guaranteeing competitiveness and the survival 
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of research institutions. The main point is to identify the 
chances for development and the options for present 
action (Coelho et al, 2003). 
The Technological foresight was born in the U.S. in the 
50’s. However, in the 90’s there was an increase in such 
methodologies in developed and developing countries, 
once more companies and countries made use of these 
studies to strengthen its competitive capacity (Coelho et 
al, 2003). 
The methods and techniques used in foreseeing are hard 
to categorize. One of the categories used is the monitoring 
& intelligence systems and the other one is the trend 
analysis. In a way that these categories emphasize how 
future conditions evaluations rely on present conditions 
(Coelho et al, 2003).  
Monitoring is the process by which pieces of information 
about foreseeing are monitored, identifying its sources, 
collecting, analyzing and structuring this information for its 
use. Thus, monitoring is crucial to any foresight (Coelho et 
al, 2003). 
Malerba describes that the group of actors involved in 
sectoral systems is heterogeneous. Actors can be 
represented by companies, users, suppliers and 
organizations (2003) and the author concludes (2005) that 
the sectoral system approach enables the identification of 
"system error" and the variables that may be subject to 
guidelines / policies. Von Hippel (1998) shows the 
importance of the functional relationship between 
companies and individuals that benefit from the products, 
processes and innovations in services, bringing together 
innovators and innovation.  
Patent analysis comes from the thought that the increase 
of interest for new technologies will reflect in the growth 
of Research and Development activities and this will lead 
to an increase of patent deposits.. Therefore, it is thought 
that new technologies can be identified by the analysis of 
patent applications in some fields. The results are generally 
presented quantitatively, but their use in the decision-
making process is based on a qualitative evaluation. 
In this context, the present study intends to show the 
relevance of omeprazole, esomeprazole, rabeprazole, 
pantoprazole and lansoprazole by means of the 
technological monitoring study through invention patent 
documents from Brazilian applications as indicators of 
innovation. In this way, it intends to analyze the uptrend of 
the use of this molecule in the pharmaceutical industry, the 
importance of its patenting, its main application in the 
pharmaceutical industry as well as the major applicant (s), 
inventor (s), IPC, claims categories and the country (ies) 
holding the technology in order to try to anticipate the 
scientific and technological advances and participate in a 
way to influence in the guidance of technological 
trajectories guaranteeing competitiveness and the survival 
of industries and research institutions.  
Method 
The methodology used in the development of this paper, 
was done in three stages. The first one was the selection 
of a patent document in the pharmaceutical area that uses 
omeprazole in the European Patents Database, the 
Espacenet. The document was obtained using the 
keywords, “omeprazole or esomeprazole or rabeprazole 
or pantoprazole or lansoprazole” and the international 
patent classifications “A61K31/4439 or A61P1/04 or 
C07D401/12”. The base ep.espacenet.com, also known as 
EPODOC, is formed by a collection of more than 60 
million patent applications from almost all the countries in 
the world, existing since 1836 and weekly  updated. It also 
offers an option of patent search by families.  
The second stage was the selection of patent documents 
with the keywords, “omeprazole or esomeprazole or 
rabeprazole or pantoprazole or lansoprazole” on the topic 
field and PN=BR* in the CDerwent, EDerwent, MDerwent 
Bases with Timespan=All Years.  
The third stage was the indexing and treatment of the 
collected data at INPI Database. The analyzed documents 
were evaluated using the keywords: “omeprazole or 
esomeprazole or rabeprazole or pantoprazole or 
lansoprazole” on the abstract and title fields. 
Through the IPC analysis and appearance of key words of 
all documents found in the search, it is expected the 
possibility to observe the diversity of topics in the group of 
collected patents. 
Results 
By means of search on the website 
http://ep.espacenet.com/advancedSearch?locale=en_EP, 
using the following truncation of keywords (omeprazole or 
esomeprazole or rabeprazole or pantoprazole or 
lansoprazole) and IPC (A61K31/4439 or A61P1/04 or 
C07D401/12) it was possible to obtain 1275 documents, all 
documents were analized in order to recover only 
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Brazilian Publication Applications (BR*). The results were 
summarized in a single sheet for comparison of data. Using 
keywords in the abstract with the link OR (patoprazole or 
omeprazole or rabeprazole or esomeprazole or 
lansoprazole) and the Brazilian Patent Number (PN=BR*) 
160 results were searched in DERWENT Databases: 
http://apps.isiknowledge.com/DIIDW_AdvancedSearch_inp
ut.do?product=DIIDW&SID=4DPOGI2k@leGOFMEj6b&s
earch_mode=AdvancedSearch [Accessed March 30, 2010]. 
The program provides a comparison of the main 
depositors (Table 1), inventors (Table 2), International 
Patent Classification (Table 3) and area studied (Table 4) 
on Derwent Database. The results were summarized in a 




Table 1. Profile of the 10 largest depositors of patent applications of omeprazole and its derivatives. 
 
 
Table 2. Profile of the 10 largest inventors of patent applications of omeprazole and its derivatives. 
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Table 3. Profile of the main IPC of patent applications of omeprazole and its derivatives. 
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Another search in the INPI Database using the terms 
pantoprazole, omeprazole, lansoprazole, rabeprazole, 
esomeprazole and tenatoprazole on the abstract and title 
fields: http://pesquisa.inpi.gov.br/MarcaPatente/jsp/servimg/ 
validamagic.jsp?BasePesquisa=Patentes [Accessed February 
13, 2010]. Table 5 presents a summary of the search 
performed. Thirty-seven (37) patent applications filed in 
Brazil in the period studied were recovered. The results 
were summarized in a single sheet for comparison of 
data. 
Finally, all data were gathered and proved to be 
relevant, making a total of 212 Patent applications. 
There were the profile of the depositors (Figure 1), the 
main inventor (Figure 2), the leading International 
Patent Classification (Figure 3), the main applicant 
country (Figure 4), category of claims (Figure 5) and 
terms found in the search performed (Figure 6).  Figure 
1 shows that the principal applicant was the company 
Astrazeneca AB, with 46 invention patent applications. 
The second largest depositor was Pfizer Inc., containing 
eight patents applications.  After, the third largest 
applicant  was the company Altana Pharma AG with 6 
patent applications from 1992 to March 2010.
  
 
Figure 1. Main depositors by number of patent applications. 
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Figure 2. Graph of major inventors by number of patent applications. 
 
The results presented in Figure 2 show the heterogeneity 
of the inventors, with a low incidence of a specific name. 
The inventors were mainly BERNHARD KOHL, 
FRANCOIS SCHUTZ, SUZY CHARBIT, MICHEL 
HOMERIN, HERVE FICHEUX AND SVERKER VON 
UNGEI with five deposits of patent applications for each 
inventor. 
According to the information below, it seems that the use 
of the IPC as a source of information is extremely 
necessary when evaluating this technological area, since it 
may have different applications for omeprazole in different 
areas. From Figure 3 below different classifications were 
taken, where the main ones were C07D 401/12 and A61K 
31/4439 and A61P 1/04  which appears 50, 48 and 43 times 
respectively in the analyzed patent documents, as it can be 
observed in picture 5. It is valid to stress that this analysis 
considers all the subgroups appearing in the analyzed 
patent documents once each patent can have more than 
one international classification to refer to all protection 
categories claimed.  
This result matches each International Patent Classification 
definition that follows:  
 C07D 401/12 - Heterocyclic compounds 
containing two or more hetero rings, having nitrogen 
atoms as the only hetero atoms ring, at least one ring 
being a six-membered ring with only one nitrogen atom 
linked by a carbon chain containing aromatic rings.   
 A61K 31/4439 - Medicinal preparations containing 
organic-active ingredients, containing further heterocyclic 
ring systems, containing a five-membered ring with 
nitrogen as a hetero atom ring, e.g. omeprazole. 
A61P 1/04 - Drugs for disorders of the alimentary 
tract or the digestive system, for ulcers, gastritis or reflux 
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Figure 3. Main international patent classifications by number of patent applications 
 
As seen in Figure 4, the country that was the main 
depositor of patents related to omeprazole and its 
derivatives was the U.S. with 59 patent applications, 
followed by four other countries: Sweden, with 45 
applications, Germany, with 22 applications, India and 
France with 22 and 16 respectively. Only six were 
identified as patent applications from Brazil, indicating that 
only 2.8% of the deposits are of Brazilian residents and 
97.2% are foreign (multinational corporations) that have 
deposited via international filing (PCT).
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Figure 5 below shows that the most frequent type of 
claim was composition (125 results), then process (86 
results) and compound (77 results). In the category of 
claims, there were found 46 patents of methods and only 
three results for combination. It is worth stressing that 
the same schedule of claims may contain more than one 
different category of claim, each category is called 
"independent claim" that may be linked to the main claim 
or not. 
The most present term in the patent applications 
analyzed was omeprazole with 68 occurrences, followed 
by pantoprazole (18 data), lansoprazole (15 data), 
esomeprazole (14 data) and Rabeprazol (10 data) as 
























Figure 5. Number of patent applications and category claims. 
 
Figure 6. Kind of omeprazole and derivatives 
 
Discussion 
Among the main depositors of patent applications on 
Omeprazole and its derivatives in Brazil, there were 
identified companies, universities and research institutes 
that strive in various categories of claims: 59% in 
pharmaceutical composition, 41% in manufacturing 
process, 36% in compost, 28% in use, 22% in method and 
1% in drug combinations. 
Analyzing the countries of the depositors of patent 
applications of its derivatives Omeprazole, published 
between 1992 and March 2010, it was noticed that these 
are mainly from the USA (59 applications), followed by 
Sweden (45 applications) and Germany (22 applications). 
Brazil does not present a significant number of patent 
applications in that theme (6 applications). 
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The period from 1992 to March 2010 showed that there is 
a concentration of patent applications in a few institutions 
of American, Swiss, or German origin, and the three main 
depositors are responsible for 28% of all patent 
applications in the area. This shows that the search for 
patent protection in Brazil is being conducted mainly by 
large multinational chemical companies that use 
omeprazole and its derivatives in pharmaceuticals. The 
main depositors are Astrazeneca AB, Pfizer Inc. and Altana 
Pharma AG, with 46, 8 and 6 patent applications 
respectively. 
It is important the combination of terms related to 
omeprazole, such as "omeprazole", "pantoprazole", 
"lansoprazole", "rabeprazole" or "esomeprazole" as well as 
the use of the International Patent Classification - IPC in 
search of information needed to monitor the subject. 
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